Targeting psoriasis with new therapies

Medicinski Glasnik

关键词: psoriasis;    biologic;    alefacept;    efalizumab;    etanercept;    infliximab adalimumab;   

DOI  :  

来源: DOAJ

【 摘 要 】

The pathogenesis of psoriasis is quite complex, but there is compelling evidence that T-cell activation and resultant overproduction of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), are critical for the development and maintenance of psoriatic lesion. The recognition of psoriasis as a T-cell mediated disease has led to the development of the new biologic agents that provide selective, immunologically directed intervention with fewer side-effects and long lasting remission than traditional therapies. These agents are custom-made, protein-like molecules that include monoclonal antibodies, fusion proteins and recombinant cytokines. Several biologic agents are currently recognized for the treatment of moderate to severe psoriasis and psoriatic arthritis. These agents can be categorized into two broad classes based on their mechanism of action: the T cell inhibitors (alefacept and efalizumab) and TNF-α inhibitors (etanercept, infliximab and adalimumab).In this review, we will present an update on the progress of the new biologic agents. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.

【 授权许可】

Unknown